3 of the year’s most notable FDA nods

The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.

By Meagan Parrish • June 27, 2025

Biogen scores Cannes Festival win with dark humored campaign

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

By Alexandra Pecci • June 24, 2025

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

More drugs surpassed $10 billion in revenue last year than ever before.

By Amy Baxter • June 23, 2025

Is DTC pharma advertising coming to an end?

A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.

By Amy Baxter • June 18, 2025

The MAHA agenda won’t include expanding GLP-1 coverage — for now

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.

By Amy Baxter • June 2, 2025

AbbVie’s ADC win shows how pharma can break through in solid tumors

 An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.

By Meagan Parrish • May 30, 2025

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.

By Michael Gibney • May 8, 2025

With TV ads under threat, here’s how pharma can leverage social media

RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.

By Amy Baxter • May 7, 2025

With compounders out of the way, Lilly and Novo go after each other

The two obesity leaders are pulling on all levers to stay on top of the market.

By Amy Baxter • May 5, 2025

Can anything threaten Novo and Lilly’s obesity market dominance?

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

By Amy Baxter • April 21, 2025

Novartis scores NFL deal to tackle health outcomes

The non-traditional marketing approach comes amid a potential crackdown on TV drug ads. 

By Amy Baxter • April 17, 2025

The industry heavyweight behind Novavax’s push to bounce back

As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

By Alexandra Pecci • March 25, 2025

Pricing transparency is in the spotlight — and that could be good news for drugmakers

An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

By Michael Gibney • March 11, 2025

With patent losses on the horizon, Amgen refocuses its business strategy

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

By Alexandra Pecci • March 5, 2025

Challenges mount for vaccine makers

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.

By Amy Baxter • Feb. 19, 2025

Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split

The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.

By Michael Gibney • Feb. 13, 2025

The kids are alright: How pharma can make inroads with Gen Z

As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

By Amy Baxter • Feb. 12, 2025

Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

By Amy Baxter • Feb. 10, 2025

Bristol Myers gives first peek at closely watched launch of schizophrenia drug

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.

By Jacob Bell • Feb. 7, 2025

With uncertainty roiling Big Pharma, execs are placing lower-risk bets

The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.

By Michael Gibney • Feb. 6, 2025

Executive hiring changes reflect a broader biotech comeback

Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.

By Alexandra Pecci • Jan. 29, 2025

Innovate or perish: Industry’s evolution leaves little room for me-too approaches

Novel drug approvals have set the stage for more breakthroughs in pharma.

By Amy Baxter • Updated Jan. 22, 2025

In pharma’s competitive climate, companies need evidence beyond clinical trials

Early planning and market research are crucial in an era of rising cost pressures.

By Kelly Bilodeau • Jan. 21, 2025

Merck is broadening its pipeline as Keytruda’s patent cliff looms

Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.

By Alexandra Pecci • Jan. 14, 2025

The ability to pivot will be ‘key’ as pharma’s tariff threat looms

Companies are looking to new countries like Vietnam for manufacturing needs, but change comes at a cost.

By Kelly Bilodeau • Jan. 13, 2025